Related references
Note: Only part of the references are listed.Hepatitis B Virus Reactivation in Lymphoma Patients With Prior Resolved Hepatitis B Undergoing Anticancer Therapy With or Without Rituximab
Winnie Yeo et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Systematic review: The effect of preventive lamivudine on hepatitis B reactivation during chemotherapy
Rohit Loomba et al.
ANNALS OF INTERNAL MEDICINE (2008)
Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan
Takeji Umemura et al.
CLINICAL INFECTIOUS DISEASES (2008)
Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection
Danny Ka-Ho Wong et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2007)
Measurement of hepatitis B virus core-related antigen as predicting factor for relapse after cessation of lamivudine therapy for chronic hepatitis B virus infection
Noboru Shinkai et al.
HEPATOLOGY RESEARCH (2006)
Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection
Atsushi Ozasa et al.
HEPATOLOGY (2006)
Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy
Chee-Kin Hui et al.
GASTROENTEROLOGY (2006)
Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy
W Yeo et al.
HEPATOLOGY (2006)
Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy
CK Hui et al.
GUT (2005)
Occult hepatitis B virus infection in hematopoietic stem cell donors in a hepatitis B virus endemic area
CK Hui et al.
JOURNAL OF HEPATOLOGY (2005)
Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy
W Yeo et al.
BRITISH JOURNAL OF CANCER (2004)
Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy
W Yeo et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Lamivudine for patients with chronic hepatitis B and advanced liver disease
YF Liaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy
TH Westhoff et al.
BLOOD (2003)
Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma
AL Cheng et al.
HEPATOLOGY (2003)
Hepatitis reactivation and liver failure in haemopoietic stem cell transplants for hepatitis B virus (HBV)/hepatitis C virus (HCV) positive recipients: a retrospective study by the Italian group for blood and marrow transplantation
A Locasciulli et al.
BONE MARROW TRANSPLANTATION (2003)
Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy
GKK Lau et al.
GASTROENTEROLOGY (2003)
Long-term safety of lamivudine treatment in patients with chronic hepatitis B
ASF Lok et al.
GASTROENTEROLOGY (2003)
Hepatitis B virus reactivation with clinical flare in allogeneic stem cell transplants with chronic graft-versus-host disease
P Seth et al.
BONE MARROW TRANSPLANTATION (2002)
Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab.
I Dervite et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
